268 related articles for article (PubMed ID: 33247391)
1. Risk of Cancer in Association with Ranitidine and Nizatidine vs Other H2 Blockers: Analysis of the Japan Medical Data Center Claims Database 2005-2018.
Iwagami M; Kumazawa R; Miyamoto Y; Ito Y; Ishimaru M; Morita K; Hamada S; Tamiya N; Yasunaga H
Drug Saf; 2021 Mar; 44(3):361-371. PubMed ID: 33247391
[TBL] [Abstract][Full Text] [Related]
2. Ranitidine Use and Incident Cancer in a Multinational Cohort.
You SC; Seo SI; Falconer T; Yanover C; Duarte-Salles T; Seager S; Posada JD; Shah NH; Nguyen PA; Kim Y; Hsu JC; Van Zandt M; Hsu MH; Lee HL; Ko H; Shin WG; Pratt N; Park RW; Reich CG; Suchard MA; Hripcsak G; Park CH; Prieto-Alhambra D
JAMA Netw Open; 2023 Sep; 6(9):e2333495. PubMed ID: 37725377
[TBL] [Abstract][Full Text] [Related]
3. Rebound hypersecretion after H2-antagonist withdrawal--a comparative study with nizatidine, ranitidine and famotidine.
Fullarton GM; Macdonald AM; McColl KE
Aliment Pharmacol Ther; 1991 Aug; 5(4):391-8. PubMed ID: 1685675
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services.
Garbis H; Elefant E; Diav-Citrin O; Mastroiacovo P; Schaefer C; Vial T; Clementi M; Valti E; McElhatton P; Smorlesi C; Rodriguez EP; Robert-Gnansia E; Merlob P; Peiker G; Pexieder T; Schueler L; Ritvanen A; Mathieu-Nolf M
Reprod Toxicol; 2005; 19(4):453-8. PubMed ID: 15749258
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the H2-receptor antagonists cimetidine, ranitidine, famotidine and nizatidine on the rabbit stomach fundus and sigmoid colon.
Kounenis G; Koutsoviti-Papadopoulou M; Elezoglou A; Voutsas A
J Pharmacobiodyn; 1992 Oct; 15(10):561-5. PubMed ID: 1362967
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording.
Savarino V; Mela GS; Zentilin P; Scalabrini P; Bonifacino G; Gambaro P; Celle G
Digestion; 1989; 42(1):1-6. PubMed ID: 2568299
[TBL] [Abstract][Full Text] [Related]
7. Ranitidine Use and Risk of Upper Gastrointestinal Cancers.
Adami HO; Trolle Andersen I; Heide-Jørgensen U; Chang ET; Nørgaard M; Sørensen HT
Cancer Epidemiol Biomarkers Prev; 2021 Dec; 30(12):2302-2308. PubMed ID: 34620629
[TBL] [Abstract][Full Text] [Related]
8. Neurotoxic convulsions induced by histamine H2 receptor antagonists in mice.
Shimokawa M; Yamamoto K; Kawakami J; Sawada Y; Iga T
Toxicol Appl Pharmacol; 1996 Feb; 136(2):317-23. PubMed ID: 8619239
[TBL] [Abstract][Full Text] [Related]
9. Ranitidine and Risk of Bladder and Kidney Cancer: A Population-Based Cohort Study.
Nørgaard M; Andersen IT; Heide-Jørgensen U; Erichsen R; Rees JR; Karagas MR; Sørensen HT
Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):45-50. PubMed ID: 34649959
[TBL] [Abstract][Full Text] [Related]
10. [Inhibition of 24-hour acidity by nizatidine].
Dammann HG; Dreyer M; Gottlieb WR; Wolf N; Müller P; Simon B
Fortschr Med; 1989 May; 107(14):321-4. PubMed ID: 2568971
[TBL] [Abstract][Full Text] [Related]
11. Effects of H2-receptor antagonists on gastric alcohol dehydrogenase activity.
Caballería J; Baraona E; Deulofeu R; Hernández-Muñoz R; Rodés J; Lieber CS
Dig Dis Sci; 1991 Dec; 36(12):1673-9. PubMed ID: 1684149
[TBL] [Abstract][Full Text] [Related]
12. [Effects of various histamine H2-receptor antagonists on gastrointestinal motility and gastric emptying].
Ohira Y; Hanyu N; Aoki T; Hashimoto Y; Iikura M; Fukuda S
J Smooth Muscle Res; 1993 Aug; 29(4):131-42. PubMed ID: 7907895
[TBL] [Abstract][Full Text] [Related]
13. Clinical review of histamine2 receptor antagonists.
Lipsy RJ; Fennerty B; Fagan TC
Arch Intern Med; 1990 Apr; 150(4):745-51. PubMed ID: 1970232
[TBL] [Abstract][Full Text] [Related]
14. Head-column field-amplified sample stacking in capillary electrophoresis for the determination of cimetidine, famotidine, nizatidine, and ranitidine-HCl in plasma.
Wu SM; Ho YH; Wu HL; Chen SH; Ko HS
Electrophoresis; 2001 Aug; 22(13):2717-22. PubMed ID: 11545397
[TBL] [Abstract][Full Text] [Related]
15. Drug interactions of H2-receptor antagonists.
Bachmann KA; Sullivan TJ; Jauregui L; Reese J; Miller K; Levine L
Scand J Gastroenterol Suppl; 1994; 206():14-9. PubMed ID: 7863246
[TBL] [Abstract][Full Text] [Related]
16. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
Dammann HG; Gottlieb WR; Walter TA; Dreyer M; Müller P; Simon B; Keohane P
Hepatogastroenterology; 1986 Oct; 33(5):217-20. PubMed ID: 2879782
[TBL] [Abstract][Full Text] [Related]
17. 300 mg nizatidine at night versus 300 mg ranitidine at night in patients with duodenal ulcer. A multicentre trial in Europe.
Simon B; Cremer M; Dammann HG; Hentschel E; Keohane PP; Mulder H; Müller P; Sarles H
Scand J Gastroenterol Suppl; 1987; 136():61-70. PubMed ID: 2892257
[TBL] [Abstract][Full Text] [Related]
18. Nizatidine versus ranitidine in the treatment of peptic ulcer disease: report on the Dutch investigation as part of a European multicentre trial.
Kuipers EJ; Hazenberg HJ; Quik RF; Hazenberg BP; de Zwart PA
Neth J Med; 1990 Aug; 37(1-2):58-62. PubMed ID: 1977089
[TBL] [Abstract][Full Text] [Related]
19. The 24-hour acid suppression profile of nizatidine.
Dammann HG; Gottlieb WR; Walter TA; Müller P; Simon B; Keohane P
Scand J Gastroenterol Suppl; 1987; 136():56-60. PubMed ID: 2892256
[TBL] [Abstract][Full Text] [Related]
20. Twice daily nizatidine or ranitidine is superior to once daily dosing in elevating 24 h intragastric pH in patients with duodenal ulcer disease.
Thomson AB; Mahachai V; Bailey RJ; Kirdeikis P; Zuk L; Marriage B; Simpson I; Jamali F
J Gastroenterol Hepatol; 1996 Dec; 11(12):1171-6. PubMed ID: 9034938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
